Watch Ticker

Intellia Therapeutics, Inc

Go to Intellia Therapeutics, Inc Website

$12.10

0.61 (5.31%)

Live

Previous Close

$12.12

Day Range

$11.505 - $12.305

Previous Day Range

$11.17 - $11.61

Market Cap

$1.2 billion USD

Day Vol.

3.4 million

Previous Day Vol.

5.1 million

Currency

USD

Primary Exchange

Nasdaq

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a rev...

Community

0 posts discussing

2

Watchers

3

Visitors

Recent News

Bragar Eagel & Squire, P.C. - INTELLIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Law firm investigating potential claims against Intellia Therapeutics following a class action complaint alleging breach of fiduciary duties related to the discontinuation of NTLA-3001 research and a 27% workforce reduction.

Related tickers: NTLA.

Read Full Article

N/A - Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Intellia Therapeutics announced positive three-year data from a Phase 1 trial of its gene editing therapy lonvo-z for hereditary angioedema (HAE). The data showed a 98% mean reduction in monthly HAE attack rate and all 10 patients were attack-free and treatment-free for a median of 23 months.

Related tickers: NTLA.

Read Full Article

Trending Tickers

Please sign in to view